Latest Safety News

Vulcan Steel Limited reported a challenging first half of FY25 with significant declines in revenue, EBITDA, and net profit, yet maintained a solid 10% return on capital employed and declared a cautious interim dividend.

Zenith Minerals has secured Program of Work approval to launch a new drilling campaign at its Dulcie Far North gold project, following a 40% resource increase. The company is also advancing development studies and exploring multiple new regional gold targets.

Alterity Therapeutics has raised A$40 million through a two-tranche placement to advance its lead compound ATH434 for neurodegenerative diseases, including Multiple System Atrophy and Parkinson's disease.

Eskan Company has received conditional approval for C$13.5 million in funding from Canada’s Critical Minerals Infrastructure Fund to advance the Trans-Atikh Project, a key infrastructure initiative supporting lithium development in Quebec’s Eeyou Istchee James Bay region.

CLINUVEL has released preliminary data from its CUV052 study showing SCENESSE® is well tolerated in adolescent erythropoietic protoporphyria (EPP) patients, supporting a planned label extension in 2025.

PYC Therapeutics has secured regulatory approval to initiate human trials of PYC-003, a novel drug candidate targeting the root cause of Polycystic Kidney Disease (PKD). Initial safety and efficacy data are expected within 2025, marking a critical step in addressing a disease affecting millions worldwide.

JB Hi-Fi Limited reported a robust 9.8% increase in HY25 sales to AUD 5.67 billion and an 8.0% rise in net profit, supported by its recent acquisition of e&s Trading Co. Despite strong momentum, the company remains cautious about competitive pressures ahead.

KGL Resources Limited has released a comprehensive feasibility study update for its Jervois Copper Project, confirming its technical robustness and financial viability with plans to commence production in 2027. The project boasts a post-tax net present value of A$405 million and aims to produce around 30,000 tonnes of copper annually, positioning itself to capitalize on a tightening global copper market.

Ansell Limited reports robust FY25 half-year results, driven by strong organic sales and EBIT growth, while accelerating its KBU integration and productivity initiatives.

Nyrada has secured ethics approval to begin its first-in-human Phase Ia trial of NYR-BI03, a promising neuro- and cardioprotective drug candidate. Recruitment starts soon, with dosing expected by March and results due in Q3 2025.

Invex Therapeutics reports a significant reduction in net loss for H1 FY2025 alongside promising pre-clinical data for Exenatide in Alzheimer’s Disease models.

Lanthanein Resources has completed diamond drilling at its Lady Grey Project, targeting a significant EM conductor plate aligned with gold anomalies. Approval for further drilling under a higher-grade anomaly sets the stage for potential resource expansion.